GoodRx (NASDAQ:GDRX) Trading Up 9.4% – Should You Buy?

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) traded up 9.4% on Monday . The company traded as high as $1.97 and last traded at $2.0450. 816,222 shares were traded during mid-day trading, a decline of 74% from the average session volume of 3,153,104 shares. The stock had previously closed at $1.87.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on GDRX shares. Wall Street Zen lowered GoodRx from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. UBS Group lowered their price objective on GoodRx from $4.25 to $4.00 and set a “neutral” rating for the company in a research report on Thursday, November 6th. Barclays initiated coverage on shares of GoodRx in a report on Monday, December 8th. They set an “underweight” rating and a $3.00 price target for the company. TD Cowen reduced their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, November 10th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of GoodRx in a research note on Tuesday, December 23rd. Five analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, GoodRx has a consensus rating of “Hold” and an average target price of $4.33.

GoodRx Stock Up 15.2%

The firm’s 50-day moving average price is $2.51 and its two-hundred day moving average price is $3.26. The company has a debt-to-equity ratio of 0.78, a quick ratio of 2.61 and a current ratio of 2.61. The firm has a market cap of $731.47 million, a PE ratio of 24.17, a P/E/G ratio of 0.71 and a beta of 1.52.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Wednesday, February 25th. The company reported $0.09 EPS for the quarter, hitting the consensus estimate of $0.09. GoodRx had a net margin of 3.82% and a return on equity of 9.31%. The firm had revenue of $194.79 million for the quarter, compared to analyst estimates of $193.27 million. During the same period last year, the business earned $0.09 EPS. GoodRx’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, equities research analysts expect that GoodRx Holdings, Inc. will post 0.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GDRX. Meridian Wealth Management LLC acquired a new stake in shares of GoodRx in the fourth quarter valued at approximately $29,000. Quarry LP purchased a new stake in GoodRx in the 3rd quarter valued at $33,000. MML Investors Services LLC acquired a new stake in GoodRx during the 4th quarter worth $36,000. DRW Securities LLC purchased a new position in GoodRx during the 4th quarter worth $40,000. Finally, Boothbay Fund Management LLC purchased a new position in GoodRx during the 3rd quarter worth $43,000. Institutional investors and hedge funds own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.